Biofarm targets a 16% increase in turnover in 2022

Biofarm, one of the most important drug producers in Romania, estimates a 16% increase in turnover for this year, after recording a value of 239 million lei and an EBITDA of approximately 2021 in 2021 82 million lei, and for 2022 it aims to increase it by 15% compared to the end of the year.   “We ended the year 2021 with very good results and we are confident that the investments budgeted for this year will ...

Developed by Codecraftsman